Intracoronary nitroprusside in the prevention of the no-reflow phenomenon in acute myocardial infarction

Chinese Medical Journal

Volumn 122, Issue 22, 2009, Pages 2718-2723

  Pan, Wei ^a   Wang, Lan Feng ^a   Yu, Jia Hui ^a   Fan, Ying ^a   Yang, Shu Sen ^a   Zhou, Li Jun ^a   Li, Yue ^a   Li, Wei Min ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Acute myocardial infarction; Nitroprusside; No reflow phenomenon; Prognosis

Indexed keywords

ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CLOPIDOGREL; GLYCERYL TRINITRATE; NITROPRUSSIDE SODIUM; TIROFIBAN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; FEMALE; HEART VENTRICLE WALL MOTION; HUMAN; INTRACORONARY INFUSION; MAJOR CLINICAL STUDY; MALE; NO REFLOW PHENOMENON; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS;

ACUTE DISEASE; ADULT; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; C-REACTIVE PROTEIN; CORONARY ANGIOGRAPHY; CORONARY CIRCULATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; NITROPRUSSIDE; PEPTIDE FRAGMENTS;

EID: 73449099925     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2009.22.008     Document Type: Article

References (25)

1. Zhang Q, Zhang RY, Qiu JP, Jin HG, Zhang JF, Wang XL, et al. Impact of different clinical pathways on outcomes of patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: the RAPID-AMI study. Chin Med J 2009; 122: 636-642.
2. Zhang Q, Zhang RY, Qiu JP, Zhang JF, Wang XL, Jiang L, et al. Prospective multicenter randomized trial comparing physician versus patient transfer for primary percutaneous coronary intervention in acute ST-segment elevation myocardial infarction. Chin Med J 2008; 121: 485-491.
3. Yip HK, Wu CJ, Chang HW, Fang CY, Yang CH, Chen SM, et al. Effect of the PercuSurge GuardWire device on the integrity of microvasculature and clinical outcomes during primary transradial coronary intervention in acute myocardial infarction. Am J Cardiol 2003; 92: 1331-1335.
4. Resnic FS, Wainstein M, Lee MK, Behrendt D, Wainstein RV, Ohno-Machado L, et al. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J 2003; 145: 42-46.
5. Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation 2002; 105: 656-662.
6. Myers PR, Banitt PF, Guerra R Jr, Harrison DG. Characteristics of canine coronary resistance arteries: importance of endothelium. Am J Physiol 1989; 257 (2 Pt 2): H603-H610.
7. Hillegass WB, Dean NA, Liao L, Rhinehart RG, Myers PR. Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experience. J Am Coll Cardiol 2001; 37: 1335-1343.
8. Shinozaki N, Ichinose H, Yahikozawa K, Shimada H, Hoshino K. Selective intracoronary administration of nitroprusside before balloon dilatation prevents slow reflow during percutaneous coronary intervention in patients with acute myocardial infarction. Int Heart J 2007; 48: 423-433.
9. Pasceri V, Pristipino C, Pelliccia F, Granatelli A, Speciale G, Roncella A, et al. Effects of the nitric oxide donor nitroprusside on no-reflow phenomonon during coronary interventions for acute myocardial infarction. Am J Cardiol 2005; 95: 1358-1361.
10. Antoniucci D, Valenti R, Migliorini A, Moschi G , Bolognese L, Cerisano G, et al. Direct infarct artery stenting without predilation and no-reflow in patients with acute myocardial infarction. Am Heart J 2001; 142: 684-690.
11. Carden DL, Granger DN. Pathophysiology of ischemia reperfusion injury. J Pathol 2000; 190: 255-266.
12. Kuo L, Chilian WM, Davis MJ. Interaction of pressure- and flow-induced responses in porcine coronary resistance vessels. Am J Physiol 1991; 261: H1706-H1715.
13. Kurz MA, Lamping KG, Bates JN. Mechanisms responsible for the heterogeneous coronary microvascular response to nitroglycerin. Circ Res 1991; 68: 847-855.
14. Parikh KH, Chag MC, Shah KJ, Shah UG, Baxi HA, Chandarana AH, et al. Intracoronary boluses of adenosine and sodium nitroprusside in combination reverses slow/no-reflow during angioplasty: a clinical scenario of ischemic preconditioning. Can J Physiol Pharmacol 2007; 85: 476-482.
15. Wei K, Kaul S. The coronary microcirculation in health and disease. Cardiol Clin 2004; 22: 221-231.
16. Eeckhout E, Kern MJ. The coronary no-reflow phenomenon: A review of mechanism and therapies. Eur Heart J 2001; 22: 729-739.
17. Reffelman T, Kloner RA. The "on-reflow" phenomenon: Basic science and clinical correlates. Heart 2002; 87: 162-168.
18. Hillegass WB, Dean NA, Liao L, Rhinehart RG, Myers PR. Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary intervention: intial human clinical experience. J Am Coll Cardiol 2001; 37: 1335-1343.
19. Li JJ, Fang CH. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases. Med Hypotheses 2004; 62: 499- 506.
20. Xiaozhou H, Jie Z, Li Z, Liyan C. Predictive value of the serum level of N-terminal pro-brain natriuretic peptide and high-sensitivity C-reactive protein in left ventricular remodeling after acute myocardial infarction. J Clin Lab Anal 2006; 20: 19-22.
21. Li DB, Hua Q, Liu Z, Li J, Xu LQ, Wang S, et al. Association between inflammatory mediators and angiographic morphologic features indicating thrombus formation in patients with acute myocardial infarction. Chin Med J 2009; 122: 1738-1742.
22. Tapanainen JM, Lindgren KS, Mäkikallio TH, Vuolteenaho O, Leppäluoto J, Huikuri HV. Natriuretic peptides as predictors of non-sudden and sudden cardiac death after acute myocardial infarction in the beta-blocking era. J Am Coll Cardiol 2004; 43: 757-763.
23. Jiang CY, Li N, Wang JA. Use of B-type natriuretic peptide in evaluation of early percutaneous coronary intervention in patients with acute coronary syndrome. Chin Med J 2004; 117: 1130-1134.
24. Wu CJ, Chang HW, Hung WC, Yang CH, Chen YH, Su CY, et al. N-terminal pro-brain natriuretic peptide is a biomarker of congestive heart failure and predictive of 30-day untoward clinical outcomes in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 2006; 70: 163-168.
25. Amit G, Cafri C, Yaroslavtsev S, Fuchs S, Paltiel O, Abu-Ful A, et al. Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial. Am Heart J 2001; 52: 887, e9-e14.